140 related articles for article (PubMed ID: 32694701)
1. Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib.
Buckley AM; Dunne MR; Morrissey ME; Kennedy SA; Nolan A; Davern M; Foley EK; Clarke N; Lysaght J; Ravi N; O'Toole D; MacCarthy F; Reynolds JV; Kennedy BN; O'Sullivan J
Sci Rep; 2020 Jul; 10(1):12105. PubMed ID: 32694701
[TBL] [Abstract][Full Text] [Related]
2. Pyrazinib (P3), [(E)-2-(2-Pyrazin-2-yl-vinyl)-phenol], a small molecule pyrazine compound enhances radiosensitivity in oesophageal adenocarcinoma.
Buckley AM; Dunne MR; Lynam-Lennon N; Kennedy SA; Cannon A; Reynolds AL; Maher SG; Reynolds JV; Kennedy BN; O'Sullivan J
Cancer Lett; 2019 Apr; 447():115-129. PubMed ID: 30664962
[TBL] [Abstract][Full Text] [Related]
3. Visceral Adipose Tissue Modulates Radiosensitivity in Oesophageal Adenocarcinoma.
Mongan AM; Lynam-Lennon N; Doyle SL; Casey R; Carr E; Cannon A; Conroy MJ; Pidgeon GP; Brennan L; Lysaght J; Reynolds JV; O'Sullivan J
Int J Med Sci; 2019; 16(4):519-528. PubMed ID: 31171903
[TBL] [Abstract][Full Text] [Related]
4. Silencing microRNA-330-5p increases MMP1 expression and promotes an invasive phenotype in oesophageal adenocarcinoma.
Bibby BAS; Miranda CS; Reynolds JV; Cawthorne CJ; Maher SG
BMC Cancer; 2019 Aug; 19(1):784. PubMed ID: 31391080
[TBL] [Abstract][Full Text] [Related]
5. Energy Metabolism, Metabolite, and Inflammatory Profiles in Human Ex Vivo Adipose Tissue Are Influenced by Obesity Status, Metabolic Dysfunction, and Treatment Regimes in Patients with Oesophageal Adenocarcinoma.
O'Connell F; Mylod E; Donlon NE; Heeran AB; Butler C; Bhardwaj A; Ramjit S; Durand M; Lambe G; Tansey P; Welartne I; Sheahan KP; Yin X; Donohoe CL; Ravi N; Dunne MR; Brennan L; Reynolds JV; Roche HM; O'Sullivan J
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980567
[TBL] [Abstract][Full Text] [Related]
6. Altered mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal adenocarcinoma.
Lynam-Lennon N; Maher SG; Maguire A; Phelan J; Muldoon C; Reynolds JV; O'Sullivan J
PLoS One; 2014; 9(6):e100738. PubMed ID: 24968221
[TBL] [Abstract][Full Text] [Related]
7. Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.
Donlon NE; Davern M; O'Connell F; Sheppard A; Heeran A; Bhardwaj A; Butler C; Narayanasamy R; Donohoe C; Phelan JJ; Lynam-Lennon N; Dunne MR; Maher S; O'Sullivan J; Reynolds JV; Lysaght J
World J Gastroenterol; 2022 Jun; 28(21):2302-2319. PubMed ID: 35800186
[TBL] [Abstract][Full Text] [Related]
8. GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma.
Gotovac JR; Liu DS; Yates MJ; Milne JV; Macpherson AA; Simpson KJ; Eslick GD; Mitchell C; Duong CP; Phillips WA; Clemons NJ
J Pathol; 2020 Nov; 252(3):317-329. PubMed ID: 32737994
[TBL] [Abstract][Full Text] [Related]
9. PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma.
Davern M; O' Brien RM; McGrath J; Donlon NE; Melo AM; Buckley CE; Sheppard AD; Reynolds JV; Lynam-Lennon N; Maher SG; Lysaght J
Sci Rep; 2022 Feb; 12(1):3259. PubMed ID: 35228614
[TBL] [Abstract][Full Text] [Related]
10. MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation.
Allott EH; Lysaght J; Cathcart MC; Donohoe CL; Cummins R; McGarrigle SA; Kay E; Reynolds JV; Pidgeon GP
Mol Carcinog; 2013 Feb; 52(2):144-54. PubMed ID: 22121096
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.
Bibby BA; Reynolds JV; Maher SG
PLoS One; 2015; 10(7):e0134180. PubMed ID: 26221725
[TBL] [Abstract][Full Text] [Related]
12. Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma.
Buckley AM; Lynam-Lennon N; Kennedy SA; Dunne MR; Aird JJ; Foley EK; Clarke N; Ravi N; O'Toole D; Reynolds JV; Kennedy BN; O'Sullivan J
Oncotarget; 2018 Sep; 9(72):33634-33647. PubMed ID: 30263091
[TBL] [Abstract][Full Text] [Related]
13. Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production.
Beales IL; Ogunwobi OO
Int J Cancer; 2010 May; 126(9):2247-55. PubMed ID: 19739114
[TBL] [Abstract][Full Text] [Related]
14. Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma.
Melo AM; O'Brien AM; Phelan JJ; Kennedy SA; Wood NAW; Veerapen N; Besra GS; Clarke NE; Foley EK; Ravi A; MacCarthy F; O'Toole D; Ravi N; Reynolds JV; Conroy MJ; Hogan AE; O'Sullivan J; Dunne MR
Front Immunol; 2019; 10():1580. PubMed ID: 31354725
[TBL] [Abstract][Full Text] [Related]
15. pSTAT3 Levels Have Divergent Expression Patterns and Associations with Survival in Squamous Cell Carcinoma and Adenocarcinoma of the Oesophagus.
O' Sullivan KE; Michielsen AJ; O' Regan E; Cathcart MC; Moore G; Breen E; Segurado R; Reynolds JV; Lysaght J; O' Sullivan J
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890775
[TBL] [Abstract][Full Text] [Related]
16. Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment.
Milano F; Jorritsma T; Rygiel AM; Bergman JJ; Sondermeijer C; Ten Brinke A; vanHam SM; Krishnadath KK
Scand J Immunol; 2008 Dec; 68(6):616-23. PubMed ID: 19055699
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol inhibits oesophageal adenocarcinoma cell proliferation via AMP-activated protein kinase signaling.
Fan GH; Wang ZM; Yang X; Xu LP; Qin Q; Zhang C; Ma JX; Cheng HY; Sun XC
Asian Pac J Cancer Prev; 2014; 15(2):677-82. PubMed ID: 24568477
[TBL] [Abstract][Full Text] [Related]
18. Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches.
Lonie JM; Barbour AP; Dolcetti R
Cancer Treat Rev; 2021 Jul; 98():102219. PubMed ID: 33993033
[TBL] [Abstract][Full Text] [Related]
19. PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours.
Davern M; Fitzgerald MC; Buckley CE; Heeran AB; Donlon NE; McGrath J; O' Connell F; Deshpande MR; Hayes C; MacDonald J; Sheppard AD; Reynolds JV; Maher SG; Lynam-Lennon N; Murphy B; Lysaght J
Transl Oncol; 2022 May; 19():101381. PubMed ID: 35245832
[TBL] [Abstract][Full Text] [Related]
20. Identification of plasma proteins associated with oesophageal cancer chemotherapeutic treatment outcomes using SWATH-MS.
Guo N; Minas G; Synowsky SA; Dunne MR; Ahmed H; McShane R; Bhardwaj A; Donlon NE; Lorton C; O'Sullivan J; Reynolds JV; Caie PD; Shirran SL; Lynch AG; Stewart AJ; Arya S
J Proteomics; 2022 Aug; 266():104684. PubMed ID: 35842220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
